Physician profile
Sally J Belcher
NPI 1881627214
$1,164.74
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $11.90 · 2021: $65.10 · 2022: $544 · 2023: $23.87 · 2024: $45.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $220.48 | 2019-2022 | |
| Novo Nordisk INC | $161.65 | 2019-2022 | |
| Abbvie INC. | $113.73 | 2022-2024 | |
| Amgen INC. | $104.63 | 2019 | |
| Glaxosmithkline, LLC. | $84.86 | 2019-2022 | |
| Lilly USA, LLC | $69.93 | 2019-2022 | |
| Pfizer INC. | $55.90 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.04 | 2019 | |
| Abbott Laboratories | $44.60 | 2022 | |
| Astellas Pharma US INC | $37.32 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $24.23 | 2022 | |
| Axogen | $24.10 | 2022 | |
| Bausch Health US, LLC | $23.87 | 2023 | Aplenzin |
| Sanofi Pasteur INC. | $23.38 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.40 | 2022 | |
| Genzyme Corporation | $15.87 | 2021 | |
| Philips North America LLC | $14.96 | 2022 | |
| Allergan, INC. | $14.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Belcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.